KEYNOTE-522: Triple-Negative Breast Cancer (TNBC) Treatment Protocol

This video explains the KEYNOTE-522 treatment plan for patients with triple-negative breast cancer (TNBC) in a clear and simple way. We cover:

  • What KEYNOTE-522 is and why this treatment approach was developed

  • Treatment plan:

    • Neoadjuvant therapy (before surgery):

      • Paclitaxel + Carboplatin + Pembrolizumab → weekly for 12 weeks

      • Followed by AC chemotherapy (Adriamycin + Cyclophosphamide) + Pembrolizumab → every 3 weeks × 4 cycles

    • Surgery

    • Adjuvant therapy (after surgery): Pembrolizumab continues for up to 9 cycles

  • Tips for managing side effects and staying on track during treatment

Our goal is to help you understand your treatment, know what to expect, and feel informed and supported throughout your TNBC journey.

Return to Treatments
Video Survey